Cormedix Inc is a biopharmaceutical company focused on developing innovative therapies aimed at improving the lives of patients with serious medical conditions. The company primarily concentrates on treatments for infections related to catheter use and other healthcare-associated infections. Cormedix is dedicated to advancing its proprietary product candidates through clinical trials and regulatory pathways, with an emphasis on addressing unmet medical needs in the fields of nephrology and infectious diseases. Through its research and development efforts, Cormedix aims to provide effective and safe therapeutic solutions that enhance patient outcomes. Read More
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network.
The company reported net revenue of $39.1 million for the first quarter from the sales of DefenCath, above an analyst estimate of $36, as per Finchat data.
The company expects quarterly adjusted earnings before interest, taxes, depreciation, and amortisation (EBITDA) to exceed $22.5 million once final numbers are reported, exceeding expectations of $14.78 million.
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CorMedix Inc. (“CorMedix” or the “Company”) (NASDAQ: CRMD) on behalf of CorMedix stockholders. Our investigation concerns whether CorMedix has violated the federal securities laws and/or engaged in other unlawful business practices.
The company reported earnings of $0.22 per share compared with a loss of $0.26 per share in the corresponding period of 2023, owing to the launch of its lead product, DefenCath.
